非小细胞肺癌患者ERCC1表达与铂类药物化疗敏感性的相关性的系统分析

摘要/Abstract

摘要： 目的: 分析非小细胞肺癌患者切除修复交叉互补基因1(ERCC1)表达与对铂类药物治疗敏感性的相关性。方法: 电子检索Medline(1991.1-2009.12)、Pubmed、CBMDisc等数据库,对回顾性病例研究和随机对照临床试验进行总结分析。结果: 共纳入10篇文献,包括9篇回顾性病例研究和1篇随机对照临床试验。9篇回顾性病例研究资料中,7篇结果表明ERCC1表达阴性患者对铂类药物的联合化疗方案的反应率高于阳性患者(2篇结果具有统计学意义),另2篇ERCC1表达阴性患者对铂类药物的联合化疗方案的反应率低于阳性患者;1篇文献报道化疗后肿瘤进展时间ERCC1阴性组患者显著长于ERCC1阳性组患者(P<0.05);化疗后中位生存期具有统计学差异的2篇报道均为ERCC1阴性组高于ERCC1阳性组 (P<0.05)。RCT研究结果表明辅助化疗可以明显延长ERCC1阴性患者的生存期,但不能延长ERCC1阳性患者的生存期。结论: 非小细胞肺癌患者中ERCC1低表达者可以从铂类化疗方案中受益,高表达者对铂类药物的化疗敏感性差,需要更好的辅助治疗方案。ERCC1作为预测NSCLC对铂类药物化疗方案敏感性的指标并指导临床个体化治疗具有临床意义。

关键词: 非小细胞肺癌, 切除修复交叉互补基因1(ERCC1), 化疗敏感性, 铂类药物

Abstract: AIM: To evaluate the relationship between the expression of excision repair cross-complement 1 (ERCC1) gene and platinum-based chemotherapy sensitivity in non-small cell lung cancer. METHODS: Database including Medline (1991.1-2009.12), Pubmed, CBMDisc were searched and randomized clinical trials as well as retrospective case studies were collected. Meta analysis was executed using RevMan 4.2 software. RESULTS: One randomized controlled trial (RCT) and nine case reports were identified and anlyzed. The results of nine case reports indicated that the response rate of ERCC1-negative patients to platinum-based chemotherapy was obviously higher than that of ERCC1-positive patients(P=0.02). One retrospective research reported longer time to progression (TTP) (P<0.05) and two reported longer overall survival in ERCC1-negative patients (P<0.05) compared with those ERCC1-positive patients. The results of RCT indicated that adjuvant chemotherapy significantly prolonged survival among low ERCC1 expression patients compared with observation but not among patients with high ERCC1 expression. Better adjuvant regimen for high ERCC1 patients is needed.CONCLUSION: Low ERCC1 expression patients are benefit from platinum-based chemotherapy, but patients with high ERCC1 expression are not sensitive to platinum-based chemotherapy. ERCC1 is a useful biomarker to clinically predict the efficacy of adjuvant chemotherapy in NSCLC.

Key words: Non-small cell lung cancer (NSCLC), Excision repair cross-complement 1 (ERCC1), Chemotherapy sensitivity, Platinum drugs

中图分类号:

R969

徐风华, 郭荣荣, 李欣, 龙丽艳, 张桂云. 非小细胞肺癌患者ERCC1表达与铂类药物化疗敏感性的相关性的系统分析[J]. 中国临床药理学与治疗学, 2013, 18(1): 45-50.

XU Feng-hua, GUO Rong-rong, LI Xin, LONG Li-yan, ZHANG Gui-yun. Relationship between ERCC1 expression and sensitivity of platinum-based chemotherapy in NSCLC: a systematic review[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 45-50.

参考文献

[1] 中国抗癌协会肺癌专业委员会,编著.2007中国肺癌临床指南[M].北京:人民卫生出版社,2007.
[2] Siddik ZH.Cisplatin: mode of cytotoxic action and molecular basis of resistance[J]. Oncogene, 2003, 22(47): 7265-7279.
[3] Su D, Ma S, Liu P, et al.Genetic polymorphisms and treatment response in advanced non small cell lung cancer[J]. Lung Cancer, 2007, 56(2): 281-288.
[4] Rosell R, Taron M, Barnadas A, et al.Nucleotide excision repair pathways involved in cisplatin resistance in non small cell lung cancer[J]. Cancer Control, 2003, 10(4): 297-305.
[5] 黄培钰,张力,梁小曼,等.晚期非小细胞肺癌组织中ERCC,Metallothione,p53表达与铂类耐药性及预后的相关分析[J]. 癌症, 2004, 23(7): 840-845.
[6] 宁瑞玲, 宋向群, 罗元, 等. ERCC1、MT、P53和Bcl2 表达与含铂方案治疗晚期NSCLC 的关系研究[J].2006, 9(4): 373-375.
[7] 肖永营, 宋勇, 施毅, 等.非小细胞肺癌患者ERCC1蛋白表达与铂类标准方案化疗敏感性的关系研究[J]. 临床肿瘤学杂志,2007, 12(5): 339-342.
[8] 袁蕾蕾,王秀问. ERCC-1在晚期非小细胞肺癌中的表达及其与铂类药物化疗敏感性关系[J]. 华北煤炭医学院学报, 2007, 9(5): 605-607.
[9] 单利,韩志刚,刘莉,等. 晚期非小细胞肺癌ERCC1和BRCA1的表达及与顺铂耐药性的临床研究[J]. 肿瘤, 2009, 29(6): 571-574.
[10] Booton R, Ward T, Ashcroft L, et al.ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer[J]. J Thorac Oncol, 2007, 2(10): 902-906.
[11] Lord RV, Brabender J, Gandara D, et al.Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer[J]. Clin Cancer Res, 2002, 8(7): 2286-2291.
[12] Lee HW, Choi YW, Han JH, et al.Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy[J]. Lung Cancer, 2009, 65(3): 377-382.
[13] Ikeda S, Takabe K, Suzuki K.Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer[J]. Pathol Int, 2009, 59(12): 863-867.
[14] Olaussen KA, Dunant A, Fouret P, et al.DNA repair by ERCC1 in Non-Small-Cell Lung Cancer and Cidplatin-Based Adjuvant Chemotherapy[J]. N Engl J Med, 2006, 355(10): 983-991.
[15] Simon GR, Sharma S, Cantor A, et al.ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer[J]. Chest, 2005, 127(3): 978-983.
[16] Cobo M, Isla D, Massuti B, et al.Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer[J]. J Clin Oncol, 2007, 25(19): 2747-2754.